A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
← catalyst calendarNCT06138639 · readout in 259 d
Sponsored by Solid Biosciences Inc. (industry) · SLDB — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
60estimated
Sites
15
Countries
Canada, Italy, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-06 | actual | When the study began enrolling |
| Primary completion | 2027-05-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-05-06 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy
Intervention
- Genetic: SGT-003
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (AEs)
measured Day 360
Change from baseline in Microdystrophin Protein Levels
measured Day 90
Permalink · SLDB's whole pipeline · Catalyst calendar · Every registered study · What changed